Organogenesis Income Taxes 2017-2024 | ORGO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Organogenesis income taxes from 2017 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Organogenesis income taxes from 2017 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$76.8B
Chugai Pharmaceutical (CHGCY)	$66.9B
Takeda Pharmaceutical (TAK)	$42.4B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$20B
Astellas Pharma (ALPMY)	$17.7B
United Therapeutics (UTHR)	$16.6B
Summit Therapeutics (SMMT)	$16B
Neurocrine Biosciences (NBIX)	$15.3B
Shionogi (SGIOY)	$12.5B
Orion OYJ (ORINY)	$7.5B
Madrigal Pharmaceuticals (MDGL)	$7.1B
Stevanato Group S.p.A (STVN)	$6.5B
Corcept Therapeutics (CORT)	$6.4B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ionis Pharmaceuticals (IONS)	$5.2B
Ono Pharmaceutical (OPHLF)	$4.9B
Grifols, S.A (GRFS)	$4.8B
Crinetics Pharmaceuticals (CRNX)	$3.7B
Catalyst Pharmaceuticals (CPRX)	$2.9B
Recursion Pharmaceuticals (RXRX)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Centessa Pharmaceuticals (CNTA)	$2.2B
Soleno Therapeutics (SLNO)	$2.1B
Hypermarcas (HYPMY)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.9B
Indivior (INDV)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.7B
Evotec AG (EVO)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.4B